Safety and efficacy of a feed additive consisting of l‐threonine produced using Corynebacterium glutamicum KCCM 80367 for all animal species (CJ Europe GmbH) Authors: EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP), Roberto Edoardo Villa, Giovanna Azimonti, Eleftherios Bonos, Henrik Christensen, Mojca Durjava, Birgit Dusemund, Ronette Gehring, Boet Glandorf, Maryline Kouba, Marta López‐Alonso, Francesca Marcon, Giovanna Martelli, Carlo Nebbia, Alena Pechová, Miguel Prieto‐Maradona, Katerina Theodoridou, Montserrat Anguita, Matteo L. Innocenti, Elisa Pettenati, Joana Revez, Jordi Tarrés‐Call, Joana P. Firmino Published: 2026 ABSTRACT AbstractFollowing a request from the European Commission, EFSA was asked to deliver a scientific opinion on the safety and efficacy of l‐threonine produced by fermentation using the genetically modified strain of Corynebacterium glutamicum, KCCM 80367, as a nutritional additive in feed for all animal species and categories. In the manufacturing process used to obtain the product under assessment, the cells from the production strain are inactivated but not removed from the final product. The FEEDAP Panel concluded that the additive does not give rise to any safety concern regarding the genetic modification of the strain. DNA from the strain is present in the final product, but its presence does not raise any safety issue since the strain does not harbour any gene of concern. No viable cells of the strain were detected in the final product. The use of l‐threonine produced using C. glutamicum KCCM 80367 in feed is safe for the target species when supplemented in appropriate amounts to the diet according to their nutritional needs. The use of l‐threonine produced using C. glutamicum KCCM 80367 in animal nutrition is considered safe for the consumers of products from animals receiving the additive, and to the environment. With regard to the safety of users, the additive is not irritant to skin but should be considered as a skin and respiratory sensitiser. No conclusions can be reached on its eye irritation potential. Exposure of users by inhalation and dermal routes is considered a risk. The additive l‐threonine produced using C. glutamicum KCCM 80367 is regarded as an effective source of the amino acid l‐threonine for all non‐ruminant species. To be as efficacious in ruminants as in non‐ruminants, it should be protected from ruminal degradation. INTRODUCTION Background and Terms of Reference Regulation (EC) No 1831/2003 1 establishes the rules governing the Community authorisation of additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any person seeking authorisation for a feed additive or for a new use of feed additive shall submit an application in accordance with Article 7. The European Commission received a request from CJ Europe GmbH 2 for the authorisation of the additive consisting of a l‐threonine produced using the genetically modified Corynebacterium glutamicum KCCM 80367, when used as a feed additive for all animal species (category: nutritional additives; functional group: amino acids, their salts and analogues). According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the application to the European Food Safety Authority (EFSA) as an application under Article 4(1) (authorisation of a feed additive or new use of a feed additive). The dossier was received on 16 December 2022 and the general information and supporting documentation are available at https://open.efsa.europa.eu/questions/EFSA‐Q‐2022‐00873. The particulars and documents in support of the application were considered valid by EFSA as of 02 October 2023. According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars and documents submitted by the applicant, shall undertake an assessment in order to determine whether the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on the safety for the target animals, consumer, user and the environment, and on the efficacy of the feed additive consisting of l‐threonine produced using C. glutamicum KCCM 80367, when used under the proposed conditions of use (see Section 3.1.4 ). Additional information The additive consists of a l‐threonine produced using the genetically modified C. glutamicum KCCM 80367, intended to be used as a nutritional additive (functional group: amino acids, their salts and analogues) in feed for all animal species. It has not been previously authorised as a feed additive in the European Union. DATA AND METHODOLOGIES Data The present assessment is based on data submitted by the applicant in the form of a technical dossier 3 in support of the authorisation request for the use of a l‐threonine produced using C. glutamicum KCCM 80367 as a feed additive. In accordance with Article 38 of the Regulation (EC) No 178/2002 4 and taking into account the protection of confidential information and of personal data in accordance with Articles 39 to 39e of the same Regulation, and of the Decision of EFSA's Executive Director laying down practical arrangements concerning transparency and confidentiality, 5 a non‐confidential version of the dossier has been published on Open.EFSA. According to Article 32c(2) of Regulation (EC) No 178/2002 and to the Decision of EFSA's Executive Director laying down the practical arrangements on pre‐submission phase and public consultations, EFSA carried out a public consultation on the non‐confidential version of the technical dossier from 7 March to 28 March 2024 for which no comments were received. The confidential version of the technical dossier was subject to a target consultation of the interested Member States from 3 October 2023 to 3 January 2024; the comments received were considered for the assessment. The FEEDAP Panel used the data provided by the applicant together with data from other sources, such as previous risk assessments by EFSA or other expert bodies, peer‐reviewed scientific papers, other scientific reports and experts' (elicitation) knowledge, to deliver the present output. EFSA has verified the European Union Reference Laboratory (EURL) report as it relates to the methods used for the control of the l‐threonine produced using C. glutamicum KCCM 80367 in animal feed. 6 Methodologies The approach followed by the FEEDAP Panel to assess the safety and the efficacy of l‐threonine produced using C. glutamicum KCCM 80367 is in line with the principles laid down in Regulation (EC) No 429/2008 7 and the relevant guidance documents: Guidance on the assessment of the safety of feed additives for the consumer (EFSA FEEDAP Panel, 2017a), Guidance on the identity, characterisation and conditions of use of feed additives (EFSA FEEDAP Panel, 2017b), Guidance on the assessment of the safety of feed additives for the target species (EFSA FEEDAP Panel, 2017c), Guidance on the characterisation of microorganisms used as feed additives or as production organisms (EFSA FEEDAP Panel, 2018), Guidance on the assessment of the safety of feed additives for the environment (EFSA FEEDAP Panel, 2019), Guidance on the assessment of the safety of feed additives for the users (EFSA FEEDAP Panel, 2023), Guidance on the assessment of the efficacy of feed additives (EFSA FEEDAP Panel, 2024) and EFSA statement on the requirements for whole genome sequence analysis of microorganisms intentionally used in the food chain (EFSA, 2024). ASSESSMENT The subject of the assessment is l‐threonine produced using the genetically modified C. glutamicum KCCM 80367. In the manufacturing process used to obtain the product under assessment, the cells of the production strain are inactivated but not removed from the final product. The additive is intended to be used as a nutritional additive (functional group: amino acids, their salts and analogues) in feed for all animal species. Characterisation Manufacturing process l‐Threonine is produced by fermentation with C. glutamicum KCCM 80367. 8 ■■■■■ 9 ■■■■■ 10 ■■■■■■■■■■ The applicant declared that no antimicrobials are used in the manufacturing process. 11 Characterisation of the strain C. glutamicum KCCM 80367 l‐Threonine is produced using a genetically modified strain of C. glutamicum, which is deposited in the Korean Culture Collection of Microorganisms (KCCM) with the accession number KCCM 80367. 12 The taxonomic identification of KCCM 80367 was confirmed ■■■■■ 13 ■■■■■ ■■■■■ The susceptibility of the strain KCCM 80367 to relevant antibiotics was tested ■■■■■ ■■■■■). 14 All measured minimum inhibitory concentration values were ■■■■■ and, therefore, the strain is considered to be susceptible to all the relevant antimicrobials. The WGS data of the strain were interrogated for the presence of antimicrobial resistance (AMR) genes ■■■■■. 15 ■■■■■■■■■■ 16 ■■■■■ (EFSA BIOHAZ Panel, 2023) ■■■■■. Therefore, it can be concluded that the strain does not harbour acquired AMR genes. Information related to the genetically modified microorganism Characterisation of the recipient or parental microorganism ■■■■■. Description of the genetic modification ■■■■■. 17 ■■■■■ ■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■. 18 ■■■■■. All the genetic modifications, including the intended and unintended ones, were reported and no concerns were identified. 19 ■■■■■ (see Section 3.1.2 ). In the context of this application, C. glutamicum KCCM 80367 is used for the production of l‐threonine for which the cells of the production strain are inactivated but not removed from the final product. The FEEDAP Panel considers that the stability of the genetic traits as well as their rate and level of expression are not relevant for a product with non‐viable cells. The level of expression of the new genetic trait is only relevant with respect to the l‐threonine concentration in the final product, as described in Section 3.1.3 . Characterisation of the additive l‐Threonine (International Union of Pure and Applied Chemistry [IUPAC] name: (2S,3R)‐2‐amino‐3‐hydroxybutanoic acid; synonyms: 2‐amino‐3‐hydroxybutyric acid, α‐amino‐β‐hydroxybutyric acid), a compound identified with the Chemical Abstracts Service (CAS) No 72–19.5 and the European Inventory of Existing Commercial Chemical Substances (EINECS) No 200‐774‐1, has a molecular weight of 119.12 g/mol. The molecular formula of l‐threonine is C4H9NO3 and its structural formula is given in Figure 1. Molecular structure of l‐threonine. The additive is l‐threonine produced using C. glutamicum KCCM 80367, for which the cells of the production strain are inactivated but not removed from the final product, and it is specified to contain ≥75% l‐threonine on a dry matter (DM) basis and ≤5% moisture. 20 Table 1 shows results of the different compositional analysis, and Table 2 shows the amino acid profile, organic acids, mineral content and trace elements in five independent batches of the additive. 21 The results showed an average of 84.6% threonine (83%–85.7%) on DM basis. The chiral purity of l‐threonine was analysed and the l‐enantiomer confirmed. 22 TABLE 1Results of analysis to determine the composition of the additive (% as is, five batches).AverageRangeThreonine (1) (free, %)83.481.9–84.4Moisture (%)1.41.4–1.5Ash (%)0.70.6–0.8Nitrogen (%)11.711.6–11.7Crude fat (%)0.60.5–0.6Crude fibre (%)< 0.5Starch (%)< 0.2Total sugars (2) (%)< 0.5Ammonium nitrogen (mg/kg)41302670–5240 Note: <: means below the limit of quantification (LOQ) of the analytical method used. (1) The active substance was analysed by the EU official method (Regulation 152/2009, Annex III F). (2) Calculated as sucrose. Results of analysis to determine the composition of the additive (% as is, five batches). Note: <: means below the limit of quantification (LOQ) of the analytical method used. The active substance was analysed by the EU official method (Regulation 152/2009, Annex III F). Calculated as sucrose. TABLE 2Results of total amino acid profile, 23 organic acids, mineral content and trace element of the additive (% as is, five batches).AverageRange Amino acids (%) Threonine (1) 75.774.4–77.5Lysine0.490.41–0.61Methionine0.140.11–0.15Cystine< 0.5Tryptophan0.060.06–0.07Glutamic acid1.271.16–1.34Proline0.260.25–0.27Glycine1.070.99–1.15Alanine0.810.77–0.85Valine0.510.47–0.55Isoleucine1.091.03–1.13Leucine0.660.6–0.7Tyrosine0.190.18–0.2Phenylalanine0.350.33–0.37Arginine0.440.41–0.46 Organic acids (%) Citric acid< 0.0004Malic acid< 0.0006Succinic acid0.040.03–0.05Lactic acid0.730.61–0.82Formic acid< 0.0006Acetic acid0.0240.02–0.029 Minerals and trace elements (%) (2) Chloride< 0.040.0260.023–0.048Calcium< 0.50.030.02–0.05Phosphorous0.130.12–0.13Sodium0.060.05–0.060.060.05–0.06Potassium< 0.250.180.16–0.20Sulphur0.540.49–0.61Sulphate1.541.4–1.8Copper0.00004–0.00006Iron0.00276–0.00391Zinc0.00011–0.00013Magnesium0.02728–0.032540.0310.026–0.035Manganese0.00211–0.00257Ammonium0.460.39–0.51Phosphate0.120.096–0.143Phosphorous, calculated as phosphate0.390.36–0.41 Note: <: means below the limit of quantification (LOQ) of the analytical method used, except for the organic acids, for which it means below the limit of detection (LOD). (1) Analysed in six batches. ■■■■■ (2) Chloride, calcium, sodium, potassium and magnesium were analysed with two different analytical methods, therefore two rows for each element are reported. Copper, iron, zinc, manganese and magnesium (one of the two methods) content were analysed in four batches of the additive. Results of total amino acid profile, 23 organic acids, mineral content and trace element of the additive (% as is, five batches). Note: <: means below the limit of quantification (LOQ) of the analytical method used, except for the organic acids, for which it means below the limit of detection (LOD). Analysed in six batches. ■■■■■ Chloride, calcium, sodium, potassium and magnesium were analysed with two different analytical methods, therefore two rows for each element are reported. Copper, iron, zinc, manganese and magnesium (one of the two methods) content were analysed in four batches of the additive. The data provided showed compliance with the specifications set by the applicant. Based on the above analytical results, the FEEDAP Panel notes that 94.2% (as is basis) of the additive has been characterised (sum of total amino acids, moisture, ash, fat, fibre, starch and total sugars). The data provided by the applicant on the impurities 24 and physicochemical and technological properties 25 of the additive are reported in Table 3. Magnesium and trace elements used in the manufacturing were also analysed (Table 2). TABLE 3Data on the impurities and physicochemical and technological properties of l‐threonine produced using C. glutamicum KCCM 80367. The data presented are ranges for all parameters.ParameterRange# batches Impurities Lead (mg/kg)< 0.0153Mercury (mg/kg)< 0.013Cadmium (mg/kg)< 0.013Arsenic (mg/kg)< 0.043Dioxins and furans (upper bound) (1) PCDD/Fs (ng WHO2005‐TEQ/kg)0.05683PCDD/Fs + PCBs (ng WHO2005‐TEQ/kg)0.11613nDL‐PCBs (μg/kg)0.533Mycotoxins (μg/kg)Aflatoxins (B1, G1, B2, G2)< 0.23Fumonisins (B1, B2, B3)< 503Ochratoxin A< 0.53Deoxynivalenol< 103Zearalenone< 53T‐2 Toxin< 23HT‐2 Toxin< 23Nucleotides (%)Cytidine‐5‐monophosphate■■■■■5Guanosine‐5‐monophosphate■■■■■5Uridine‐5‐monophosphate■■■■■5Inosine‐5‐monophosphate■■■■■5Adenosine‐5‐monophosphate■■■■■5Biogenic amines (mg/kg)2‐Phenylethylamine■■■■■5Cadaverine■■■■■5Histamine■■■■■5Putrescine■■■■■5Spermidine■■■■■5Spermine■■■■■5Tryptamine■■■■■5Tyramine■■■■■■■■■■■■■■■5 Microbial contamination Salmonella spp. (per 25g)Not detected3 Enterobacteriaceae (per 10g)Not detected3 Escherichia coli (per 10g)Not detected3Yeast and moulds (CFU/g)< 1003 Physical properties Physical formPale/dark brown free‐flowing granulesBulk density (kg/m3)740–7473Dusting potential (Stauber Heubach) (mg/m3)140–3653Particle size distribution (laser diffraction) (% of particles below, v/v)3100 μm4.6–8.750 μm1.3–2.710 μm0.5–0.91 μm0.1–0.2 Shelf‐life (% losses) 25°C/60% RH 3 months0.4–0.6340°C/75% RH 6 months0–0.23 Stability in premixtures (% losses) Chicken for fattening, 25°C/60% RH 6 months03 Stability in feed (% losses) Chicken for fattening, mash feed, 25°C/60% RH 3 months9–223Chicken for fattening, pelleted feed, 25°C/60% RH 3 months1–223Pelleting 72–73°C0–5 Homogeneity (coefficient of variation, %) Chicken for fattening, premixture5.51Chicken for fattening, mash feed11.81Chicken for fattening, pelleted feed7.41 Note: <: means below the limit of quantification (LOQ) of the analytical method used.Abbreviations: PCBs, polychlorinated biphenyls; PCDDs, polychlorinated dibenzo‐p‐dioxins; PCDFs, polychlorinated dibenzofurans; nDL‐PCBs, non‐dioxin‐like PCBs; TEQ, toxic equivalent factors for dioxins, furans and dioxin‐like PCBs established by WHO in 2005 (Van den Berg et al., 2006); WHO, World Health Organization. (1) Upper bound concentrations are calculated on the assumption that all values of the different congeners below the LOQ are equal to the LOQ. Values are expressed per kg of additive with 88% dry matter content. Data on the impurities and physicochemical and technological properties of l‐threonine produced using C. glutamicum KCCM 80367. The data presented are ranges for all parameters. Note: <: means below the limit of quantification (LOQ) of the analytical method used. Abbreviations: PCBs, polychlorinated biphenyls; PCDDs, polychlorinated dibenzo‐p‐dioxins; PCDFs, polychlorinated dibenzofurans; nDL‐PCBs, non‐dioxin‐like PCBs; TEQ, toxic equivalent factors for dioxins, furans and dioxin‐like PCBs established by WHO in 2005 (Van den Berg et al., 2006); WHO, World Health Organization. Upper bound concentrations are calculated on the assumption that all values of the different congeners below the LOQ are equal to the LOQ. Values are expressed per kg of additive with 88% dry matter content. The FEEDAP Panel notes the high levels of biogenic amines, especially cadaverine, which deserve attention/monitoring during the manufacturing process. The FEEDAP Panel considers that the microbial contamination and the amounts of the detected impurities do not raise safety concerns. This includes also the residues of the ■■■■■, for which, taking into account its nature (and amount present in the additive), a separate assessment is done in Appendix A . The presence of viable cells of the strain was investigated ■■■■■. 26 ■■■■■ No viable cells were detected. The presence of DNA of the strain in the final product was demonstrated ■■■■■. 27 ■■■■■ DNA from the production strain was detected in all the samples tested. Conditions of use l‐Threonine produced using C. glutamicum KCCM 80367 is intended to be used in feed for all animal species, directly or through complementary feed or premixtures. No inclusion levels have been proposed, as the requirements of l‐threonine, in quantitative terms, depend on the nutrient composition, in particular the amino acid composition of the un‐supplemented diet, the species, the age and the physiological state of the animal, the performance level and the environmental conditions. Safety Safety of C. glutamicum KCCM 80367 C. glutamicum KCCM 80367 is a genetically modified strain developed to increase the production of l‐threonine. The strain belongs to a species, C. glutamicum, that is included in the qualified presumption of safety (QPS) list when used for production purposes (EFSA BIOHAZ Panel, 2026). For the product under assessment, the qualifications are the safety of the genetic modifications, the absence of acquired AMR genes and the absence of viable cells of the strain in the final product. The taxonomic identification of the strain KCCM 80367 was unequivocally established, the genetic modifications do not raise safety concerns, no acquired AMR genes are present and viable cells were not detected in the final product. Therefore, the strain fulfils the requirements for the QPS approach. DNA from the strain is present in the final product, but its presence does not raise any safety issue, since the strain does not harbour any gene of concern. Consequently, the FEEDAP Panel concludes that the additive does not pose any safety concern regarding the genetically modified strain C. glutamicum KCCM 80367. Toxicological studies The applicant provided toxicological studies with the product under assessment. Genotoxicity studies, including mutagenicity Bacterial reverse mutation test In order to investigate the potential of l‐threonine produced using C. glutamicum KCCM 80367 to induce gene mutations in bacteria, an Ames test was performed according to the OECD Testing Guideline (TG) 471 and claimed Good Laboratory Practice (GLP) compliant. 28 The experiments were done using strains of Salmonella Typhimurium (TA98, TA100, TA1535 and TA1537) plus the strain of Escherichia coli (WP2 uvrA) in the presence and absence of metabolic activation (S9 fraction). Two independent experiments were conducted applying the plate incorporation and pre‐incubation methods both in the presence and absence of metabolic activation. Based on the results of the preliminary experiment, the examined test concentrations were 15.81, 50, 158.1, 500, 1581 and 5000 μg/plate in first and second tests, plus the concentration of 5 μg/plate in the second experiment. The test item was dissolved in deionised water. Appropriate positive and negative control chemicals were used, and the background mean numbers of revertant colonies were in the historical control range. No toxicity and no increase in the mean number of revertant colonies were observed with any tester strain and at any of the tested concentrations. The FEEDAP Panel concludes that the test item did not induce gene mutations in bacteria under the experimental conditions employed in this study. In vitro mammalian cell micronucleus test In order to investigate the potential of l‐threonine produced using C. glutamicum KCCM 80367 to induce chromosome damage, an in vitro micronucleus test was performed in mouse lymphoma L5178Y TK+/− 3.7.2 C cell line following the OECD TG 487 (2016) and claimed GLP compliant. 29 The test item was dissolved at 50 mg/mL in distilled water, sonicated 5 min in ultrasonic water bath and appropriate dilutions were prepared in water. Based on the results of a preliminary cytotoxicity test, three or four concentrations were selected for the analysis of micronuclei: 111.11, 333.33 and 1000 μg/mL for the 3h‐treatment with metabolic activation followed by 21 h of recovery; 500, 1000 and 2000 μg/mL for the 3h‐treatment without metabolic activation (plus 21 h of recovery), and 166.67, 500, 1000 and 2000 μg/mL for the long treatment (24 h) without metabolic activation. After the exposure period, the version of the test without cytochalasin B was used. Cells collected by centrifugation and were transferred for growth through the recovery period (21 h). No recovery was used for 24 h continuous treatment. None of the treatment concentrations caused a significant increase in the number of micronucleated cells when compared to the appropriate negative (vehicle) control value in the experiments with and without metabolic activation. Appropriate positive and negative control chemicals were used, and the results obtained confirmed that the experimental system was sensitive and valid. The negative control data were within the historical range for the spontaneous frequency of micronucleated cells. The positive controls caused significant increases in the number of micronucleated cells in the experiments with or without metabolic activation. The FEEDAP Panel concludes that the test item did not induce chromosome damage in vitro in mammalian cells under the experimental conditions employed in this study. Repeated dose toxicity studies 90‐day study In a 90‐day toxicity study, four groups of 10 animals/sex/group of Wistar rats were administered by oral gavage with l‐threonine produced using C. glutamicum KCCM 80367 diluted in corn oil (10 mL/kg bw per day) at dose levels of 0, 500, 1000 and 2000 mg/kg bw per day for 90 consecutive days followed by a 4 weeks recovery period (5/sex/control and highest dose level). 30 The highest dose corresponds to 22,222.2 mg/kg complete feed (EFSA Scientific Committee, 2012). The study was performed following OECD TG 408 and claimed GLP compliant. A total of four animals were found dead during the first 2 weeks of the study because of misgavage in all cases, confirmed by histopathology. Since the deaths occurred early in the study reserve animals were used to replace them. There were no test item related adverse clinical signs observed during the study. Lower body weight gain was observed in high‐dose males and females and in mid dose females, with a body weight difference of about 7–10% at 90 days; this was considered test item related and correlated with slightly lower food intake in high‐dose males. However, during the recovery period, partial recovery of these parameters was seen. In the absence of pathology findings these differences are not considered to be adverse. No test item related changes were seen during neurological assessments and ophthalmoscopy. No changes were observed in haematology and coagulation parameters. In clinical chemistry, relatively minor changes were seen in urea, electrolytes, cholesterol and HDL in mid and high‐dose males and/or females. Increased kidney weights were probably related to excretion of test item, which may have caused minor functional changes. However, in the absence of any correlated histopathological findings, these clinical chemistry and renal differences were not considered as adverse. No test item related adverse changes were observed in urinalysis. There were no clearly test item related changes seen in thyroid hormone levels. Statistical differences in T4 values in mid and high‐dose males were not correlated with other hormone changes and there were no changes observed in thyroid gland weight or histopathology. It is considered that the test item had no adverse effect on thyroid function. No changes in the oestrus cycle of females or for males during sperm evaluation were observed. The test item did not cause any adverse organ weight change, macroscopic or microscopic changes. Under the conditions of this study, there were some minor effects (body weight gain, food consumption, clinical chemistry) in Wistar rats with the test item, however, none of them was considered as adverse. In conclusion, under the conditions of the study, the highest dose tested of 2000 mg l‐threonine/kg body weight/day did not show any adverse effect. Conclusions on toxicological studies The FEEDAP Panel concludes that the additive did not show any genotoxicity potential. Moreover, the results obtained in a sub‐chronic oral toxicity study raised no concerns regarding the product. Safety for the target species, consumer and the environment The Panel considers that safety concerns from the use of this product would not derive from the amino acids present in the additive, provided that they are supplemented at appropriate amounts to satisfy the nutritional needs of the animals. Concerns may arise from the unidentified part of the additive, which amounts to approximately 6%, and contains residues from the fermentation. The impurities present, including those from manufacturing, were of no concern (see Section 3.1.3 and Appendix A ). The strain and its genetic modification raised no concerns (see Section 3.2.1 ), and the toxicological studies performed with the additive under assessment identified no concerns (see Section 3.2.2 ). The l‐threonine requirements of the target animal species and the safety of this essential amino acid in non‐ruminant and ruminant nutrition are well known to feed formulators and available in general publications on animal nutrition. Therefore, the Panel concludes that the use of the additive l‐threonine produced using C. glutamicum KCCM 80367 is safe for the target species when used to satisfy their amino acid requirements. The absorption and metabolic fate of l‐threonine in the organism is well known and well described in the scientific literature. The amino acid l‐threonine, supplemented to feed, will be incorporated into proteins of tissues and/or products of animal origin and any of its potential excess will be metabolised and excreted. Therefore, the composition of tissues and products of animal origin will not be affected by the use of supplemental l‐threonine in animal nutrition. Therefore, the FEEDAP Panel considers that the use of the additive in animal nutrition is safe for the consumer. The amino acid l‐threonine is a physiological and natural component of animal and plant proteins. When consumed, it will be absorbed, and the non‐absorbed fraction will be incorporated into the intestinal microbial mass and excreted as such. The use of the additive l‐threonine in animal nutrition would not lead to any localised increase in its concentration in the environment. Environmental risk assessment of horizontal gene transfer for the additive, for which the cells of the production strain are inactivated but not removed from the final product, is only needed in case genes of concern (e.g. AMR genes) are present in the strain under assessment due to potential environmental selection of the encoded trait(s) after transfer. No genes of concern (e.g. AMR genes) are present in C. glutamicum KCCM 80367, therefore, no further environmental risk assessment is needed. The use of l‐threonine produced using C. glutamicum KCCM 80367 as a feed additive does not represent a risk to the environment. Safety for the user The skin irritation potential of the additive was tested in a skin irritation study performed according to the OECD TG 439, 31 which showed that the additive is not a skin irritant (UN GHS ‘No Category’). The eye irritation potential of the additive was tested in a study performed according to the OECD TG 437. 32 The results are inconclusive, thus no prediction can be made regarding its irritation potential to eyes. The skin sensitisation potential of the additive was tested in a study performed according to the OECD TG 429, 33 which showed that the additive is not a skin sensitiser (UN GHS ‘No Category’). However, the FEEDAP Panel notes that the OECD test guidelines available at present are designed to assess the skin sensitisation potential of chemical substances only and that currently no validated assays for assessing the sensitisation potential of microbial‐based products are available. Therefore, considering the nature of the additive, it should be considered as a skin and respiratory sensitiser. Conclusions on safety for the user The additive l‐threonine produced using C. glutamicum KCCM 80367 is not irritant to skin but should be considered as a skin and respiratory sensitiser. No conclusions can be reached on its eye irritation potential. Exposure of users by inhalation and dermal routes is considered a risk. Efficacy Efficacy studies are not required for amino acids that occur naturally in plant and animal proteins. The nutritional role of the amino acid l‐threonine is well established in the scientific literature. l‐Threonine produced using C. glutamicum KCCM 80367 is regarded as an efficacious source of that amino acid for non‐ruminant animal species. For the supplemental l‐threonine to be as efficacious in ruminants as in non‐ruminant species, it would require protection against degradation in the rumen. Post‐market monitoring The FEEDAP Panel considers that there is no need for specific requirements for a post‐market monitoring plan other than those established in the Feed Hygiene Regulation 34 and Good Manufacturing Practice. CONCLUSIONS The additive is l‐threonine produced using the genetically modified strain C. glutamicum KCCM 80367. In the manufacturing process used to obtain the product under assessment, the cells of the production strain are inactivated but not removed from the final product. The additive was characterised up to 94.2%; therefore, the following conclusions apply only to the product obtained with the manufacturing process described in this application. Viable cells were not detected in the additive. DNA from the strain is present in the additive and is not considered of concern. Consequently, the additive does not give rise to any safety concern regarding the genetically modified strain and the additive resulting from its fermentation. The use of l‐threonine produced using C. glutamicum KCCM 80367 in feed is safe for the target species, consumers and environment. With regard to the safety for the user, the additive is not irritant to skin, but should be considered as a skin and respiratory sensitiser. No conclusions can be reached on the eye irritation potential. Exposure of users by inhalation and dermal routes is considered a risk. The additive is regarded as an effective source of the essential amino acid l‐threonine for all animal species. However, in order to be efficacious in ruminants as in non‐ruminants, it should be protected from ruminal degradation. ABBREVIATIONS antimicrobial resistance ■■■■■ body weight Chemical Abstracts Service colony forming unit coefficient of variation dry matter European Inventory of Existing Chemical Substances European Union Reference Laboratory EFSA Scientific Panel on Additives and Products or Substances used in Animal Feed Good Laboratory Practice International Union of Pure and Applied Chemistry limit of detection limit of quantification non‐dioxin‐like PCBs no observed adverse effect level Organisation for Economic Co‐operation and Development polychlorinated biphenyls polychlorinated dibenzo‐p‐dioxins qualified presumption of safety relative humidity replicative population doubling toxic equivalent United Nations Globally Harmonised System of Classification and Labeling of Chemicals ■■■■■ World Health Organization REQUESTOR European Commission QUESTION NUMBERS EFSA‐Q‐2022‐00873 COPYRIGHT FOR NON‐EFSA CONTENT EFSA may include images or other content for which it does not hold copyright. In such cases, EFSA indicates the copyright holder and users should seek permission to reproduce the content from the original source. PANEL MEMBERS Roberto Edoardo Villa, Giovanna Azimonti, Eleftherios Bonos, Henrik Christensen, Mojca Durjava, Birgit Dusemund, Ronette Gehring, Boet Glandorf, Maryline Kouba, Marta López‐Alonso, Francesca Marcon, Giovanna Martelli, Carlo Nebbia, Alena Pechová, Miguel Prieto‐Maradona, Katerina Theodoridou. LEGAL NOTICE The published scientific output includes information items that have been redacted, in accordance with the confidentiality requests submitted by the applicant, pending a decision thereon by EFSA. Redactions may be subject to review once a decision on such confidentiality requests is taken by EFSA.